{
    "nctId": "NCT03899792",
    "briefTitle": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",
    "officialTitle": "A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors",
    "overallStatus": "RECRUITING",
    "conditions": "Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Advanced Solid Tumors: Dose Limiting Toxicities (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies\n* Evidence of an activating RET gene alteration in the tumor and/or blood\n* Measurable or non-measurable disease\n* Karnofsky (participants 16 years and older) or Lansky (participants younger than 16) performance score of at least 50\n* Participant with primary CNS tumors or cerebral metastases must be neurologically stable for 7 days prior and must not have required increasing doses of steroids within the last 7 days\n* Adequate hematologic, hepatic and renal function.\n* Ability to receive study drug therapy orally or via gastric access\n* Willingness of men and women of reproductive potential to observe conventional and effective birth control\n\nExclusion Criteria:\n\n* Major surgery within two weeks prior to planned start of LOXO-292\n* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292\n* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection\n* Clinically significant active malabsorption syndrome\n* Pregnancy or lactation\n* Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the participant required a modification to current thyroid medication in the 7 days before start of LOXO-292)\n* Uncontrolled symptomatic hypercalcemia or hypocalcemia\n* Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet\u00ae SF and OraPlus\u00ae, for participants who will receive LOXO-292 suspension\n* Prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor\\[s\\])",
    "sex": "ALL",
    "minimumAge": "6 Months",
    "stdAges": "CHILD, ADULT"
}